Menopause & Midlife Health

Much longer than most women expect — and much longer than providers used to say. Research shows that 87% of women with hot flashes experience them every single day, and about 1 in 3 has more than 10 episodes per day. The old estimate of "6 months to 2 years" has been revised significantly.

Studies now report median durations of 4 to over 10 years. Women who start having hot flashes during perimenopause — before their final period — tend to experience them longest. This is exactly why treatment matters: for many women, waiting it out is simply not a realistic strategy. The good news is that effective treatment, including HRT and non-hormonal options, can meaningfully reduce both frequency and severity.

This is the most common concern we hear — and it deserves a careful answer. The fear comes from the 2002 Women's Health Initiative (WHI) study, which found a slightly increased risk of breast cancer and cardiovascular events. But that study used oral conjugated equine estrogen combined with a synthetic progestin (medroxyprogesterone acetate) — older formulations that most providers no longer prescribe as first choice.

Modern hormone therapy — particularly transdermal estradiol (delivered as a patch, gel, or spray) with micronized progesterone — has a different and more favorable safety profile. Transdermal estradiol bypasses the liver and is associated with a lower risk of blood clots than oral estrogen. Micronized progesterone is body-identical and appears to carry a lower breast cancer risk than synthetic progestins.

For most healthy women under 60, or within 10 years of their final period, the benefits of hormone therapy outweigh the risks — per ACOG and the 2023 NAMS Hormone Therapy Position Statement. The decision is always individualized based on your health history.

No — but stopping is worth planning. Studies show that about 50% of women experience a return of hot flashes and other symptoms after stopping HRT, regardless of how long they took it or whether they stopped gradually or all at once.

The decision to continue or stop HRT should be based on your symptoms and individual risk-benefit picture — not a fixed time limit. ACOG guidance is clear: the decision to continue HRT is individualized, and some women benefit from continuing well past age 65. We review this with you at every visit so you always have current, personalized guidance.

Several non-hormonal options have genuine clinical evidence — though none are quite as effective as HRT for vasomotor symptoms:

• Fezolinetant (Veozah) — FDA-approved in 2023, specifically designed for moderate-to-severe hot flashes. Works by targeting the neurokinin 3 pathway in the brain that triggers vasomotor symptoms. The first non-hormonal mechanism of this kind.
• Paroxetine 7.5 mg/day (Brisdelle) — the only other FDA-approved non-hormonal medication specifically for vasomotor symptoms. SSRIs and SNRIs including venlafaxine and escitalopram also have strong evidence and are widely used.
• Gabapentin — particularly helpful for night sweats and sleep disruption from hot flashes.
• Cognitive behavioral therapy (CBT) — doesn't reduce the number of hot flashes, but significantly reduces how disruptive they are to daily life. Meaningful evidence from multiple trials.

What doesn't have meaningful evidence: phytoestrogens, black cohosh, and most herbal supplements. ACOG does not recommend these as primary treatment for hot flashes.

If you have a uterus — yes. Estrogen alone without a progestogen can cause the uterine lining to overgrow (endometrial hyperplasia), which increases the risk of endometrial cancer over time. Adding progesterone or a progestogen prevents this.

If you have had a hysterectomy — no. You can take estrogen alone, which carries a different (generally more favorable) risk profile than combined therapy.

Micronized progesterone (Prometrium) is the preferred form — it's chemically identical to the progesterone your body produces, and has a better sleep and mood profile compared to older synthetic progestins like medroxyprogesterone acetate (the one used in the WHI study).

No. If vaginal dryness, irritation, or pain during sex are your primary concerns, local vaginal estrogen is the recommended first-line treatment — and it is not the same as systemic HRT.

Low-dose local estrogen (cream, ring, or tablet) works directly on vaginal and urinary tissue. Systemic absorption is minimal, making it safe for most women — including many who cannot take systemic HRT. Vaginal estrogen is not subject to the same cardiovascular or breast cancer risk concerns as oral systemic estrogen.

For women who prefer a non-estrogen option, ospemifene (Osphena) is an FDA-approved oral medication for pain during sex caused by vaginal atrophy. Vaginal DHEA (Intrarosa) is another FDA-approved option that works locally without systemic estrogen.

All FDA-approved routes effectively relieve vasomotor symptoms — but they differ in how they're absorbed and their risk profiles:

• Transdermal (patch, gel, or spray) — estrogen is absorbed through the skin, bypassing the liver entirely. This "first-pass" bypass means a lower risk of blood clots compared to oral estrogen. Most guidelines favor transdermal delivery, especially for women with risk factors.
• Oral estrogen — absorbed through the gut and processed by the liver, which can affect clotting factors and lipid levels. Effective, but carries a slightly higher blood clot risk than transdermal. Some women prefer this route for convenience.
• Low-dose vs. standard dose — lower doses are associated with fewer side effects (breast tenderness, bloating, headaches) while still providing meaningful symptom relief. Starting low and adjusting is a common approach.

The right choice depends on your personal health history, lifestyle, and preferences — something we work through together at your appointment.